Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of ATL-962 for weight loss in obese patients with type 2 diabetes on metformin
2004-000254-23Phase 2Completed
- Sponsor
- Alizyme Therapeutics
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cetilistat in obesity and type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Alizyme Therapeutics. Primary endpoint: Absolute weight loss from baseline. Started Sep 2004; status: completed.
02
Drugs
cetilistat
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-000254-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000254-23.